Navigation Links
Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Date:8/11/2008

BEIJING, Aug. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that it will hold its 2007 Annual Meeting of Shareholders on Thursday, September 4, 2008 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple Street, St. John's, Antigua. All shareholders of record as of August 1, 2008 will be eligible to vote and are invited to attend.

Sinovac Biotech Ltd.'s 2007 Annual Report, notice of annual general meeting and proxy statement are available on the investors section of the Company's website http://www.sinovac.com .

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors:

Stephanie Carrington

The Ruth Group

Tel: +1-646-536-7017

Email: scarrington@theruthgroup.com

Media:

Janine McCargo

The Ruth Group

Tel: +1-646-536-7033

Email: jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Crucial Life Sciences Data Solutions, ... greatly improves performance of the platform. In particular, Version 4.1 boosts performance for ... data to be collected on a per patient basis. Clinical Studio has employed ...
(Date:5/5/2016)... ... May 05, 2016 , ... American Process, Inc. (API) announced ... Patent Nos. 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® ... hydrophobic nanocellulose compositions. In addition to these patents and U.S. Patent No. ...
(Date:5/4/2016)... , ... May 05, 2016 , ... ... proud to support the National Stroke Association during National Stroke Awareness Month in ... Facebook and Twitter pages throughout the month. CereScan will donate $1 up ...
(Date:5/4/2016)... WHIPPANY, N.J. , May 4, 2016 /PRNewswire/ ... evaluating its oncology compound Stivarga ® (regorafenib) ... hepatocellular carcinoma (HCC) has met its primary endpoint ... The study, called RESORCE, evaluated the efficacy and ... disease has progressed after treatment with sorafenib. The ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):